Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XT-150 in Neuropathic Pain
NCT04466410Phase 1Terminated
- Sponsor
- Xalud Therapeutics
- Start
- Apr 2021
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of XT-150 in neuropathic pain (4 arms), sponsored by Xalud Therapeutics. Primary endpoints: Number of participants with Treatment-Emergent Adverse Events and Serious Adverse Events at 6 months, Number of participants with abnormal vital signs at 6 months and 6 more. Started Apr 2021; status: terminated.
02
Drugs
XT-150
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04466410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04466410.